<p>New York, New York--(Newsfile Corp. - August 24, 2026) - <a href="https://api.newsfilecorp.com/re...

<p>New York, New York--(Newsfile Corp. - August 24, 2026) - <a href="https://api.newsfilecorp.com/redirect/ppBBNf3MVo">Kaplan Fox &#38; Kilsheimer LLP</a> is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/FULC">FULC</a>).</p><p style="text-align: center;"><a href="https://api.newsfilecorp.com/redirect/YEPPeHxNE8">CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION</a></p><p><b>If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may </b><a href="https://api.newsfilecorp.com/redirect/0p44yf51am"><b>CLICK HERE</b></a><b> to contact us. You may also contact Kaplan Fox by emailing </b><a href="mailto:jcampisi@kaplanfox.com"><b>jcampisi@kaplanfox.com</b></a><b> or by calling (212) 329-8571.</b></p><p>Fulcrum Therapeutics is a "clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with rare hematological disorders[.]"</p><p>On June 1, 2026, after market close, Fulcrum Therapeutics announced in a press release "the discontinuation of its pociredir program for the treatment of SCD [(sickle cell disease).]" The Company stated that the "meeting minutes from recent end-of-phase interactions with the [U.S. Food and Drug Administration ("FDA")]" "reflected heightened FDA concerns regarding pociredir's benefit-risk profile in SCD, stemming from an unexpectedly high rate of secondary hematologic malignancies observed with Tazverik&#174; (tazemetostat), another PRC2 inhibitor, which was withdrawn from the global market in March 2026." After submitting further information, the FDA "concluded that any pharmacological intervention targeting the PRC2 complex carries equivalent malignancy risk regardless of the specific subunit engaged."  As a result, the Company has "no viable regulatory path forward for further clinical development of pociredir."</p><p>Following this news, the price of Fulcrum Therapeutics stock declined from a closing price on June 1, 2026 of $6.42 per share to close at $3.14 per share on June 2, 2026, a decline of $3.28 per share, or by 51.09%.</p><p><b>WHY CONTACT KAPLAN FOX?</b></p><p>Kaplan Fox &#38; Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.</p><p>Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in <i>In re Bank of America&#8212;</i>the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act&#8212;$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in <i>ATRS v. Allianz Global Investors</i>, and a $475 million settlement in <i>In re Merrill Lynch</i>.</p><p>For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.</p><p>This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.</p><p>If you have any questions about this investigation, please contact:</p><div id="contactInfo"><p><b>CONTACT:</b><br />Jeffrey P. Campisi<br /><a href="https://api.newsfilecorp.com/redirect/RYmmeUwVnA">KAPLAN FOX &#38; KILSHEIMER LLP</a><br />800 Third Avenue, 38th Floor<br />New York, New York 10022<br />(212) 329-8571<br /><a href="mailto:jcampisi@kaplanfox.com">jcampisi@kaplanfox.com</a></p><p>Laurence D. King<br /><a href="https://api.newsfilecorp.com/redirect/WAooeSn8ew">KAPLAN FOX &#38; KILSHEIMER LLP</a><br />1999 Harrison Street, Suite 1501<br />Oakland, California 94612<br />(415) 772-4704<br /><a href="mailto:lking@kaplanfox.com">lking@kaplanfox.com</a></p></div><p>Contacting or submitting information to Kaplan Fox &#38; Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.</p><p><a href="https://api.newsfilecorp.com/redirect/B500ytpaN0">https://www.kaplanfox.com/case/fulcrum-therapeutics-inc-investigation-learn-more-now/</a></p><p id="corporateNewsLogoContainer"><img src="https://images.newsfilecorp.com/files/12532/311014_eb91155f04922bd3_logo.jpg" id="corporateNewsLogo" alt="Corporate Logo" /></p><p id="corporateLinkBack">To view the source version of this press release, please visit <a href="https://api.newsfilecorp.com/redirect/5WQQyU52RB">https://www.newsfilecorp.com/release/311014</a></p><p><img src="https://api.newsfilecorp.com/newsinfo/311014/197" alt="" /></p>

FULC

Kaplan Fox Announces an Investigation into Fulcrum Therapeutics, Inc. (FULC) on Behalf of Investors

Fulcrum Therapeutics under securities probe amid pociredir setback and FDA concerns

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>&lt;p&gt;New York, New York--(Newsfile Corp. - August 24, 2026) - &lt;a href=&quot;https://api.newsfilecorp.com/re...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Kaplan Fox &amp; Kilsheimer LLP has initiated a securities investigation into Fulcrum Therapeutics. The catalyst is Fulcrum&#039;s June 1, 2026, announcement that pociredir for sickle cell disease was discontinued after FDA safety concerns linked to PRC2 inhibitor malignancy risk. The stock plunged, signaling heightened regulatory and litigation risk for FULC, though the release cites no new price-sensitive facts.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Kaplan Fox launches Fulcrum securities investigation; no specific findings disclosed.</li><li>Fulcrum discontinues pociredir for SCD after FDA-related safety concerns.</li><li>FDA concerns tied to PRC2 inhibitor malignancy risk; stock drops ~51%.</li><li>Legal inquiry adds sentiment risk but no new price-relevant facts.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Fulcrum Therapeutics, Inc. (FULC)</strong>: Subject of the investigation; pociredir program discontinued due to FDA safety concerns.</li><li><strong>Epizyme, Inc. (EPZM)</strong>: Tazverik PRC2 inhibitor safety issues cited as context for broader regulatory risk to similar programs.</li><li><strong>Kaplan Fox &amp; Kilsheimer LLP (N/A)</strong>: Plaintiffs&#039; firm behind the inquiry; potential catalyst for litigation, no direct price data.</li></ul>
  </section>

  <section data-block="category">
    <h3>Legal</h3>
    <p>Category: Legal. The item is a securities-law inquiry tied to a biopharma, creating potential litigation and regulatory risk that can affect FULC sentiment and volatility, independent of ongoing development data.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Kaplan Fox securities inquiry into Fulcrum adds sentiment risk.</li><li>Pociredir discontinuation following FDA concerns pressures FULC sentiment.</li><li>June 1 close $6.42; June 2 close $3.14, down 51.09%.</li><li>Regulatory risk for PRC2 inhibitors may affect peers like EPZM.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Fulcrum Therapeutics discontinued pociredir for SCD on June 1, 2026.</li><li>FDA concerns cited due to malignancy risk observed with PRC2 inhibitors (Tazverik) and March 2026 global withdrawal of that drug.</li><li>FDA concluded any PRC2-targeting intervention carries comparable malignancy risk regardless of subunit engaged.</li><li>Fulcrum&#039;s June 1 close: $6.42; June 2 close: $3.14; price decline 51.09%.</li><li>Kaplan Fox &amp; Kilsheimer LLP issued the investigation and contact details on August 24, 2026.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Near-term bearish bias; relief requires clear litigation or regulatory-path updates within weeks.</p>
  </section>
</section>


<article>
  <header>
    <h2>Kaplan Fox Announces Investigation into Fulcrum Therapeutics, Inc. (FULC) on Behalf of Investors</h2>
  </header>

  <p>New York, New York--(Newsfile Corp. - August 24, 2026) - Kaplan Fox &amp; Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: <strong>FULC</strong>).</p>

  <p style="text-align: center;"><a href="https://api.newsfilecorp.com/redirect/YEPPeHxNE8"><strong>CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION</strong></a></p>

  <section id="investor-notice">
    <h3>Investor Notice and How to Participate</h3>
    <p><strong>If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may</strong> <a href="https://api.newsfilecorp.com/redirect/0p44yf51am"><strong>CLICK HERE</strong></a> <strong>to contact us. You may also contact Kaplan Fox by emailing</strong> <a href="mailto:jcampisi@kaplanfox.com"><strong>jcampisi@kaplanfox.com</strong></a> <strong>or by calling (212) 329-8571.</strong></p>
  </section>

  <section id="about-company">
    <h3>Company Overview</h3>
    <p>Fulcrum Therapeutics is a <em>"clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with rare hematological disorders[.]"</em></p>
  </section>

  <section id="investigation-details">
    <h3>Disclosures Related to the Pociredir Program</h3>
    <p>On <strong>June 1, 2026</strong>, after market close, Fulcrum Therapeutics announced in a press release <em>"the discontinuation of its pociredir program for the treatment of SCD [(sickle cell disease).]"</em> The Company stated that the <em>"meeting minutes from recent end-of-phase interactions with the [U.S. Food and Drug Administration ("FDA")]"</em> <em>"reflected heightened FDA concerns regarding pociredir's benefit-risk profile in SCD, stemming from an unexpectedly high rate of secondary hematologic malignancies observed with Tazverik® (tazemetostat), another PRC2 inhibitor, which was withdrawn from the global market in March 2026."</em> After submitting further information, the FDA <em>"concluded that any pharmacological intervention targeting the PRC2 complex carries equivalent malignancy risk regardless of the specific subunit engaged."</em> <strong>As a result, the Company has</strong> <em>"no viable regulatory path forward for further clinical development of pociredir."</em></p>
  </section>

  <section id="market-impact">
    <h3>Market Reaction to the Announcement</h3>
    <p>Following this news, the price of Fulcrum Therapeutics stock declined from a closing price on <strong>June 1, 2026</strong> of <strong>$6.42</strong> per share to close at <strong>$3.14</strong> per share on <strong>June 2, 2026</strong>, a decline of <strong>$3.28</strong> per share, or by <strong>51.09%</strong>.</p>
    <ul>
      <li><strong>Ticker:</strong> <em>FULC</em> on NASDAQ</li>
      <li><strong>June 1 closing:</strong> <strong>$6.42</strong> per share</li>
      <li><strong>June 2 closing:</strong> <strong>$3.14</strong> per share</li>
      <li><strong>Reported decline:</strong> <strong>$3.28</strong> per share, <strong>51.09%</strong></li>
    </ul>
    <p><em>This represents a substantial one-day decline following the regulatory update.</em></p>
  </section>

  <section id="about-kaplan-fox">
    <h3>About Kaplan Fox &amp; Kilsheimer LLP</h3>
    <p><strong>Kaplan Fox &amp; Kilsheimer LLP</strong> is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than <strong>$10 billion</strong> for clients and the classes it has represented.</p>
    <p>Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a <strong>$2.425 billion</strong> recovery on behalf of Bank of America shareholders in <em>In re Bank of America</em>—the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act—<strong>$800 million</strong> recovered for the Arkansas Teacher Retirement System and other pension funds in <em>ATRS v. Allianz Global Investors</em>, and a <strong>$475 million</strong> settlement in <em>In re Merrill Lynch</em>.</p>
    <p>For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.</p>
  </section>

  <section id="disclaimer">
    <p><em>This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.</em></p>
  </section>

  <section id="contact-information">
    <h3>Contact Information</h3>
    <div id="contactInfo">
      <p><strong>CONTACT:</strong><br />Jeffrey P. Campisi<br /><a href="https://api.newsfilecorp.com/redirect/RYmmeUwVnA">KAPLAN FOX &amp; KILSHEIMER LLP</a><br />800 Third Avenue, 38th Floor<br />New York, New York 10022<br />(212) 329-8571<br /><a href="mailto:jcampisi@kaplanfox.com">jcampisi@kaplanfox.com</a></p>
      <p>Laurence D. King<br /><a href="https://api.newsfilecorp.com/redirect/WAooeSn8ew">KAPLAN FOX &amp; KILSHEIMER LLP</a><br />1999 Harrison Street, Suite 1501<br />Oakland, California 94612<br />(415) 772-4704<br /><a href="mailto:lking@kaplanfox.com">lking@kaplanfox.com</a></p>
    </div>
    <p>Contacting or submitting information to Kaplan Fox &amp; Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.</p>
    <p><a href="https://api.newsfilecorp.com/redirect/B500ytpaN0">https://www.kaplanfox.com/case/fulcrum-therapeutics-inc-investigation-learn-more-now/</a></p>
  </section>

  <p><img src="https://images.newsfilecorp.com/files/12532/311014_eb91155f04922bd3_logo.jpg" alt="Corporate Logo" /></p>
  <p id="corporateLinkBack">To view the source version of this press release, please visit <a href="https://api.newsfilecorp.com/redirect/5WQQyU52RB">https://www.newsfilecorp.com/release/311014</a></p>
  <p><img src="https://api.newsfilecorp.com/newsinfo/311014/197" alt="" /></p>
</article>

Kaplan Fox & Kilsheimer LLP has initiated a securities investigation into Fulcrum Therapeutics. The catalyst is Fulcrum's June 1, 2026, announcement that pociredir for sickle cell disease was discontinued after FDA safety concerns linked to PRC2 inhibitor malignancy risk. The stock plunged, signaling heightened regulatory and litigation risk for FULC, though the release cites no new price-sensitive facts.

News insight

Kaplan Fox Announces an Investigation into Fulcrum Therapeutics, Inc. (FULC) on Behalf of Investors

AI summary

Sentiment rationale

Key facts

Legal